KNOXVILLE, Tenn., May 2 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today that it has received its fifth patent for its medical device technologies (U.S. Patent 7,036,516), bringing the total patents received to-date in the U.S. to fifteen. The patent covers use of advanced laser technologies in the selective destruction of pigmented tissue, such as moles and pigmented skin cancers, including melanomas. Additional areas of applicability include selective destruction of hair follicles for hair reduction along with tattoo removal.
The Company’s patent portfolio also contains four patents related to its pharmaceutical products, including patents for its small-molecule, tumor- specific agent PV-10, also known as Provecta(TM), for the treatment of focal cancers. In addition to a clinical trial of PV-10 that is currently underway for the treatment of metastatic melanoma, the Company recently accomplished its initial Phase 1 clinical trial objectives for the treatment of recurrent breast cancer with PV-10, achieving the primary study endpoints of safety and preliminary efficacy assessment.
“Our new patent covers methods that are fundamental to a range of new medical devices that can dramatically improve the selectivity and effectiveness of treatments for important skin conditions, both in the therapeutic and cosmetic arenas,” said Craig Dees, Ph.D., Provectus CEO and co-inventor. “While our focus today is on pharmaceuticals, this patent is based on our earlier work with advanced medical devices and is an important component in a broad portfolio of technologies we’ve made available for licensure to the medical device industry.”
Provectus’ laser technologies harness the energy of lasers in a precise manner that minimizes damage to tissue surrounding the targeted treatment area. In addition, these technologies enable the selective destruction of target tissues based on their inherent light absorption.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is an innovative biopharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company’s topical agent Xantryl(TM), a treatment for psoriasis.
The Company’s offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals, Inc.
CONTACT: investors, Matt Clawson of Allen & Caron Inc, 949-474-4300, ormatt@allencaron.com; or Peter Culpepper of Provectus Pharmaceuticals Inc,865- 769-4011, or culpepper@pvct.com
Web site: http://www.pvct.com/